Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment
Abstract
:1. Introduction
2. Results
2.1. Fendiline Hydrochloride Selectively Induces NDM29 Expression in NB Cells
2.2. Fendiline Hydrochloride Reduces ABC Transporter Expression Increasing the Susceptibility of NB Cells to Cisplatin
2.3. Cisplatin and Fendiline Hydrochloride Act Synergistically in a Combo-Treatment
2.4. Co-Administration of Fendiline Hydrochloride Markedly Strengthens Cisplatin Antitumor Activity In Vivo
2.5. Co-Administration of Fendiline Hydrochloride and Cisplatin Induces Apoptosis and Reduces the Fraction of GD2+ NB Cells
3. Discussion
4. Materials and Methods
4.1. Screening Assay
4.2. Cell Cultures
4.3. qPCR Analysis
4.4. NDM29 Down-Regulation
4.5. xCELLigence System Cytotoxicity Assays
4.6. MTT Assay
4.7. Determination of Combination Index Values
4.8. Methylcellulose Colony Formation Assay
4.9. Mice
4.10. In Vivo Tumorigenic Assays
4.11. Immunohistochemical Staining
4.12. Apoptosis Analysis
4.13. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Maris, J.M.; Hogarty, M.D.; Bagatell, R.; Cohn, S.L. Neuroblastoma. Lancet 2007, 369, 2106–2120. [Google Scholar] [CrossRef]
- Jiang, M.; Stanke, J.; Lahti, J.M. The Connections Between Neural Crest Development and Neuroblastoma. Cur. Top. Dev. Biol. 2011, 94, 77–127. [Google Scholar] [CrossRef] [Green Version]
- Cheung, N.-K.V.; Dyer, M.A. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013, 13, 397–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bosse, K.R.; Maris, J.M. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 2016, 122, 20–33. [Google Scholar] [CrossRef]
- Park, J.R.; Eggert, A.; Caron, H. Neuroblastoma: Biology, Prognosis, and Treatment. Hematol. Clin. N. Am. 2010, 24, 65–86. [Google Scholar] [CrossRef]
- Mazzocco, K.; Defferrari, R.; Sementa, A.R.; Garaventa, A.; Longo, L.; De Mariano, M.; Esposito, M.R.; Negri, F.; Ircolò, D.; Viscardi, E.; et al. Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group. Pediatr. Blood Cancer 2015, 62, 1725–1732. [Google Scholar] [CrossRef]
- Colletti, M.; Di Paolo, V.; Galardi, A.; Milano, G.M.; Mastronuzzi, A.; Locatelli, F.; Di Giannatale, A.; Colletti, V.D.P.M. Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward. Anti-Cancer Agents Med. Chem. 2017, 17, 1328–1343. [Google Scholar] [CrossRef]
- Penna, I.; Vassallo, I.; Nizzari, M.; Russo, D.; Costa, D.; Menichini, P.; Poggi, A.; Russo, C.; Dieci, G.; Florio, T.; et al. A novel snRNA-like transcript affects amyloidogenesis and cell cycle progression through perturbation of Fe65L1 (APBB2) alternative splicing. Biochim. Biophys. Acta Mol. Cell Res. 2013, 1833, 1511–1526. [Google Scholar] [CrossRef] [Green Version]
- Massone, S.; Vassallo, I.; Fiorino, G.; Castelnuovo, M.; Barbieri, F.; Borghi, R.; Tabaton, M.; Robello, M.; Gatta, E.; Russo, C.; et al. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol. Dis. 2011, 41, 308–317. [Google Scholar] [CrossRef]
- Massone, S.; Vassallo, I.; Castelnuovo, M.; Fiorino, G.; Gatta, E.; Robello, M.; Borghi, R.; Tabaton, M.; Russo, C.; Dieci, G.; et al. RNA polymerase III drives alternative splicing of the potassium channel–interacting protein contributing to brain complexity and neurodegeneration. J. Cell Biol. 2011, 193, 851–866. [Google Scholar] [CrossRef]
- Ciarlo, E.; Massone, S.; Penna, I.; Nizzari, M.; Gigoni, A.; Dieci, G.; Russo, C.; Florio, T.; Cancedda, R.; Pagano, A. An intronic ncRNA-dependent regulation of SORL1 expression affecting A formation is upregulated in post-mortem Alzheimer’s disease brain samples. Dis. Model. Mech. 2012, 6, 424–433. [Google Scholar] [CrossRef] [Green Version]
- Castelnuovo, M.; Massone, S.; Tasso, R.; Fiorino, G.; Gatti, M.; Robello, M.; Gatta, E.; Berger, A.; Strub, K.; Florio, T.; et al. An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB J. 2010, 24, 4033–4046. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Massone, S.; Ciarlo, E.; Vella, S.; Nizzari, M.; Florio, T.; Russo, C.; Cancedda, R.; Pagano, A. NDM29, a RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of APP and amyloid β secretion. Biochim. Biophys. Acta Mol. Cell Res. 2012, 1823, 1170–1177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gavazzo, P.; Vella, S.; Marchetti, C.; Nizzari, M.; Cancedda, R.; Pagano, A. Acquisition of neuron-like electrophysiological properties in neuroblastoma cells by controlled expression of NDM29 ncRNA. J. Neurochem. 2011, 119, 989–1001. [Google Scholar] [CrossRef] [PubMed]
- Alloisio, S.; Viti, F.; Dante, S.; Barbieri, R.; Arnaldi, G.; Petrelli, A.; Gigoni, A.; Giannoni, P.; Quarto, R.; Nobile, M.; et al. Generation of a Functional Human Neural Network by NDM29 Overexpression in Neuroblastoma Cancer Cells. Mol. Neurobiol. 2016, 54, 6097–6106. [Google Scholar] [CrossRef] [PubMed]
- Costa, D.; Gigoni, A.; Würth, R.; Cancedda, R.; Florio, T.; Pagano, A. Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell Int. 2014, 14, 59. [Google Scholar] [CrossRef] [Green Version]
- Würth, R.; Barbieri, F.; Florio, T. New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells. Biomed Res. Int. 2014, 2014, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Würth, R.; Thellung, S.; Bajetto, A.; Mazzanti, M.; Florio, T.; Barbieri, F. Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds. Drug Discov. Today 2016, 21, 190–199. [Google Scholar] [CrossRef]
- Vella, S.; Penna, I.; Longo, L.; Pioggia, G.; Garbati, P.; Florio, T.; Rossi, F.; Pagano, A. Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. Sci. Rep. 2015, 5, 18144. [Google Scholar] [CrossRef] [Green Version]
- Bram, E.; Stark, M.; Raz, S.; Assaraf, Y.G. Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance. Neoplasia 2009, 11, 1359–IN11. [Google Scholar] [CrossRef] [Green Version]
- Chuang, L.-Y.; Guh, J.-Y.; Ye, Y.-L.; Lee, Y.-H.; Huang, J.-S. Effects of probucol on cell proliferation in human ovarian cancer cells. Toxicol. Res. 2016, 5, 331–339. [Google Scholar] [CrossRef] [PubMed]
- Chou, T.-C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984, 22, 27–55. [Google Scholar] [CrossRef]
- Topaly, J.; Zeller, W.J.; Fruehauf, S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001, 15, 342–347. [Google Scholar] [CrossRef] [Green Version]
- Chou, T.-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res. 2010, 70, 440–446. [Google Scholar] [CrossRef] [Green Version]
- Chou, T.-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 2006, 58, 621–681. [Google Scholar] [CrossRef] [PubMed]
- Woods, N.; Trevino, J.; Coppola, D.; Chellappan, S.; Yang, S.; Padmanabhan, J. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget 2015, 6, 35931–35948. [Google Scholar] [CrossRef] [Green Version]
- Van Der Hoeven, D.; Cho, K.-J.; Ma, X.; Chigurupati, S.; Parton, R.G.; Hancock, J.F. Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission. Mol. Cell. Biol. 2012, 33, 237–251. [Google Scholar] [CrossRef] [Green Version]
- Huang, C.; Huang, C.; Cheng, J.; Liu, S.; Chen, I.; Tsai, J.; Chou, C.; Tseng, P.; Jan, C.-R. Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells. Hum. Exp. Toxicol. 2009, 28, 41–48. [Google Scholar] [CrossRef]
- Cheng, J.-S.; Wang, J.-L.; Lo, Y.-K.; Chou, K.-J.; Lee, K.-C.; Liu, C.-P.; Chang, H.-T.; Jan, C.-R. Effects of the antianginal drug fendiline on Ca2+ movement in hepatoma cells. Hum. Exp. Toxicol. 2001, 20, 359–364. [Google Scholar] [CrossRef]
- Jan, C.-R.; Yu, C.-C.; Huang, J.-K. Dual effect of the antianginal drug fendiline on bladder female transitional carcinoma cells: Mobilization of intracellular CA2+ and induction of cell death. Pharmacology 2001, 62, 218–223. [Google Scholar] [CrossRef]
- Alhothali, M.; Mathew, M.; Iyer, G.; Lawrence, H.R.; Yang, S.; Chellappan, S.; Padmanabhan, J. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC. Int. J. Mol. Sci. 2019, 20, 2423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kukovetz, W.R.; Brunner, F.; Beubler, E.; Weyhenmeyer, R.; Lohaus, R.; Grob, M.; Mayer, D. Single dose pharmacokinetics of fendiline in humans. Eur. J. Drug Metab. Pharmacokinet. 1982, 7, 105–110. [Google Scholar] [CrossRef] [PubMed]
- Tallarida, R.J. An Overview of Drug Combination Analysis with Isobolograms. J. Pharmacol. Exp. Ther. 2006, 319, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- González-González, R.; Molina-Frechero, N.; Carreón-Burciaga, R.G.; López-Verdín, S.; Robles-Bonilla, C.; Pereira-Prado, V.; Bologna-Molina, R. Comparison between Manual and Automated Methods for Ki-67 Immunoexpression Quantification in Ameloblastomas. Anal. Cell. Pathol. 2016, 2016, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Yeo, M.-K.; Kim, H.E.; Kim, S.H.; Chae, B.J.; Song, B.J.; Lee, A. Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer. J. Clin. Pathol. 2017, 70, 715–719. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brizzolara, A.; Garbati, P.; Vella, S.; Calderoni, M.; Quattrone, A.; Tonini, G.P.; Capasso, M.; Longo, L.; Barbieri, R.; Florio, T.; et al. Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment. Molecules 2020, 25, 5234. https://doi.org/10.3390/molecules25225234
Brizzolara A, Garbati P, Vella S, Calderoni M, Quattrone A, Tonini GP, Capasso M, Longo L, Barbieri R, Florio T, et al. Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment. Molecules. 2020; 25(22):5234. https://doi.org/10.3390/molecules25225234
Chicago/Turabian StyleBrizzolara, Antonella, Patrizia Garbati, Serena Vella, Matilde Calderoni, Alessandro Quattrone, Gian Paolo Tonini, Mario Capasso, Luca Longo, Raffaella Barbieri, Tullio Florio, and et al. 2020. "Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment" Molecules 25, no. 22: 5234. https://doi.org/10.3390/molecules25225234